

## UPMC Hillman Cancer Center ASCO 2023 Presentations

Friday, June 2

Posters

Divya Natesan

“Differences in real-world pembrolizumab dosing patterns (every 3 weeks versus every 6 weeks) across a large cancer center network”

8 to 11 a.m.

Hall A | Abstract 2592 | Board 434

Jingxiao Jin, MD

“Interim results from a phase I/II study of duvelisib PI3K $\delta$  inhibitor and nivolumab in patients with advanced unresectable melanoma who have progressed on anti-PD1 therapy.”

1:15 to 4:15 p.m.

Abstract 9540 | Board 303

Andrew David Knight, MD

“Prognostic significance of immune-related adverse events and immunosuppression in patients with melanoma receiving adjuvant anti-PD-1 therapy.”

1:15 to 4:15 p.m.

Abstract 9580 | Board 343

Lewis Wu, MD

“A radiomic-based predictive model of lung adenocarcinoma brain metastases and molecular subtypes.”

1:15 to 4:15 p.m.

Discussion S504 | Abstract 2014 | Board 371

Saturday, June 3

Presentations

Phoung Mai, MD – Chair and Abstract

“Prevention, Risk Reduction, and Hereditary Cancer”

4:30 to 6 p.m.

S102

Annie Im, MD – Chair

Emily MacDuffie, MD – Abstract

“No One Left Behind: Enhancing Equity in Oncology/ABSTRACT - The ticking “biological clock”: Reproductive assistance, costs, and elective fertility preservation in female oncologists and trainees.”

4:30 to 6 p.m.

S100a

Monday, June 5

Posters

Robert Ferris, MD, PhD

“Outcomes by time to adjuvant therapy in E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.”

1:15 to 4:15 p.m.

Hall A | Abstract 6035 | Board 28

Presentations

Benjamin Nacev, MD, PhD

“Integrating Genomic Profiling in the Care of Patients with Sarcoma from Diagnosis to Therapy”

3 to 3:20 p.m.

E253d

Jason J. Luke, MD, FACP

“Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.”

4:24 p.m.

Hall D | Abstract LBA9505

Heath Skinner, MD, PhD

“Phase II trial of adjuvant de-escalated radiation + adjuvant nivolumab for intermediate-high risk P16+ oropharynx cancer.”

4:30 to 4:42 p.m.

E451 Poster Discussion | Abstract 6014